Alimera Sciences plans to resubmit Iluvien, a drug candidate for chronic diabetic macular edema, for FDA approval by the end of this month. Alimera licensed the drug from pSivida. The application will highlight the drug's safety profile and will focus on chronic DME patients who don't respond satisfactorily to existing treatments. The drug has been approved in the U.K., Germany, France and several other European countries. In 2011, the FDA requested additional trials.